X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.prnewswire.com/news-releases/immviras-oncolytic-product-mvr-t3011-it-intratumoral-injection-receives-fda-fast-track-designation-for-hnscc-treatment-302090155.html
https://www.prnewswire.com/news-releases/fda-approves-first-vaccine-to-prevent-disease-caused-by-chikungunya-virus-301984081.html
https://www.prnewswire.com/news-releases/immvira-appoints-howard-l-kaufman-md-as-consulting-medical-advisor-301907504.html
https://www.prnewswire.com/news-releases/immvira-presented-latest-encouraging-clinical-results-of-two-proprietary-products-at-asco-2023-301843794.html
https://www.prnewswire.com/news-releases/immviras-oncolytic-product-mvr-c5252-targeting-malignant-glioma-obtained-nmpas-approval-for-clinical-trial-in-china-301784765.html
https://www.prnewswire.com/news-releases/immvira-clinical-snapshot-intratumoral-injected-ov-mvr-t3011-it-monotherapy-achieved-median-pfs-of-12-9-months-on-treatment-of-melanoma-301742055.html
https://www.prnewswire.com/news-releases/immvira-announced-its-signing-of-series-c-financing-and-negotiation-with-further-investors-for-the-round-301659495.html
https://www.prnewswire.com/news-releases/immviras-brand-new-ohsv-product-mvr-c5252-targeting-malignant-glioma-obtained-fdas-orphan-drug-designation-301599610.html
https://www.prnewswire.com/news-releases/immviras-intravenous-administered-ohsv-mvr-t3011-iv-demonstrated-promising-clinical-biological-activities-301590242.html
https://www.prnewswire.com/news-releases/immvira-enters-clinical-development-in-combination-therapy-of-mvr-t3011-it-and-mek-inhibitor-in-the-us-301527992.html
Market Place
Share 
